GLP-1 and GIP send separate signals
Incretin hormones link eating to the body's response to glucose. GLP-1 means glucagon-like peptide-1. GIP means glucose-dependent insulinotropic polypeptide. Both names are long, so patient leaflets use the initials. Each hormone has its own receptor.
Tirzepatide, the active ingredient in Mounjaro, is a dual GIP and GLP-1 receptor agonist. Semaglutide acts on the GLP-1 receptor only. People often call tirzepatide a GLP-1 medicine. Calling it another version of semaglutide misses a real difference. You cannot swap one for the other milligram for milligram.
Trial results matter more than receptor counts
People like to rank treatments by counting receptors, as if one is good, two is better and three is best. This reasoning fails. The strength, balance and length of receptor activity all matter. So do the dose studied and how well people tolerate the medicine. A mechanism gives the scientific reason to test a drug. Clinical trials show what happened to people who took it.
When you compare results, start with who was in the study and what the trial tested. Did the participants have diabetes? Was the trial built to measure weight loss, glucose control or something else? A result from a selected trial group cannot predict how another person will respond in everyday care.
Shared safety rules and different instructions
Related medicines can cause similar stomach and bowel side effects, and most need a slow dose increase. Some safety habits overlap too. Talk about pregnancy plans, tell an anaesthetic team you take the medicine and report severe symptoms. Product instructions still differ. Missed-dose rules and storage can vary.
GIP activity does not remove the need for diet support or regular review. A licensed treatment acting on fewer receptors is still a valid choice. For you, how the medicine is given, your medical history, your past response, side effects and access may count for more than the mechanism.
Ask which medicine fits your goal
Ask which options have evidence for your goal, what the likely trade-offs are and how the plan changes if side effects become a problem. "Which is strongest?" is a narrower question. If your prescriber suggests switching, ask for a written starting schedule and a clear instruction to stop the old medicine.
You should not need a biochemistry background to follow the explanation. Leave knowing four things: the active ingredient, why it was chosen, how to take it and whom to contact. The GLP-1 and GIP difference is useful background. Those four details make the prescription usable.
A new receptor target needs regulatory approval
A newly announced receptor combination may still be in development. Promising mechanism language does not mean a regulator has approved anything. A laboratory explanation, a phase 2 result, a completed phase 3 programme and an authorised product each tell you something different.
Some articles jump straight from a hormone diagram to a claim you can buy the product. Check the national regulator and the finished medicine before you conclude there is legitimate clinical access.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- MHRA: GLP-1 medicines for weight loss and diabetes gov.uk
- NICE NG197: Shared decision making nice.org.uk
Spotted something out of date? Report a mistake.